H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Sage Therapeutics to $50 from $55 and keeps a Neutral rating on the shares post the Q3 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly